Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXB4NL)

Drug Name

MEDI4893 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Ventilator-associated pneumonia	PK81.0	Phase 2b	[1]
Hospital-acquired pneumonia	CA40.Z	Phase 1	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Staphylococcus Alpha-hemolysin (Stap-coc hly)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cyrtominetin	DM0JA9N	Phlegmy cough	SA80-SA8Z	Phase 3	[3]
AR-301	DM2YQK8	Ventilator-associated pneumonia	PK81.0	Phase 3	[4]
ASN100	DMWPGLS	Hospital-acquired pneumonia	CA40.Z	Phase 2	[5]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Staphylococcus Alpha-hemolysin (Stap-coc hly)	TT5FLYB	HLA_STAAU	Not Available	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02296320) Study of the Efficacy and Safety of MEDI4893
2	Mechanisms of neutralization of a human anti-alpha-toxin antibody. J Biol Chem. 2014 Oct 24;289(43):29874-80.
3	Molecular insight into the inhibition mechanism of cyrtominetin to alpha-hemolysin by molecular dynamics simulation. Eur J Med Chem. 2013 Apr;62:320-8.
4	Clinical pipeline report, company report or official report of Aridis Pharmaceuticals.
5	Antibacterial antibodies gain traction. Nat Rev Drug Discov. 2015 Nov;14(11):737-8.